Indications And Scheduling - NAPLEX

1. A 45-year-old female (weight 70 kg, height 165 cm) presents with allergic rhinitis symptoms (sneezing, itchy/watery eyes) that occur most days during spring. Medical history: seasonal allergic rhinitis, mild intermittent asthma. Allergies: none. Current medications: albuterol HFA 2 puffs inhaled every 4–6 hours as needed, multivitamin 1 tablet by mouth daily. Pertinent labs: not applicable; vitals stable. Which medication is indicated for this condition?
   Answer: Fluticasone propionate nasal spray 50 mcg: 2 sprays in each nostril once daily This question tests appropriate medication selection for seasonal allergic rhinitis. The patient presents with classic allergic rhinitis symptoms (sneezing, itchy/watery eyes) occurring most days during spring season, indicating persistent symptoms requiring controller therapy. Intranasal corticosteroids like fluticasone propionate are first-line therapy for persistent allergic rhinitis, providing superior symptom control compared to oral antihistamines. Amoxicillin (option B) is inappropriate as allergic rhinitis is not a bacterial infection, pantoprazole (option C) treats acid reflux not allergies, and furosemide (option D) is a diuretic unrelated to allergic symptoms. The clinical pearl is that intranasal corticosteroids are more effective than oral antihistamines for nasal congestion and should be used regularly throughout the allergy season for optimal benefit, with effects typically seen after 12-24 hours of consistent use.
2. A 74-year-old male (weight 76 kg) presents for a comprehensive medication review after a hospital discharge. Medical history: heart failure with reduced ejection fraction, hypertension, hyperlipidemia, benign prostatic hyperplasia (BPH). Allergies: none. Current medications: sacubitril/valsartan 49 mg/51 mg by mouth twice daily (new), lisinopril 20 mg by mouth daily (home med), furosemide 40 mg by mouth daily, metoprolol succinate 100 mg by mouth daily, atorvastatin 40 mg by mouth nightly, and tamsulosin 0.4 mg by mouth nightly. Pertinent labs: SCr 1.2 mg/dL (0.6–1.3), potassium 4.8 mEq/L (3.5–5.0), AST 26 U/L (10–40), ALT 22 U/L (7–56). Which medication should be discontinued based on current indications?
   Answer: Lisinopril 20 mg by mouth daily This question tests recognition of contraindicated drug combinations in heart failure management. The key issue is concurrent use of sacubitril/valsartan (an ARNI containing an ARB component) with lisinopril (an ACE inhibitor), which is contraindicated due to increased risk of angioedema and must be separated by a 36-hour washout period. Lisinopril should be discontinued immediately as the patient is already on sacubitril/valsartan for heart failure management. Tamsulosin appropriately treats BPH, furosemide manages volume status in heart failure, and atorvastatin is indicated for cardiovascular risk reduction. The clinical pearl is that ARNIs cannot be used with ACE inhibitors or within 36 hours of the last ACE inhibitor dose due to angioedema risk from dual neprilysin/ACE inhibition - this is a black box warning requiring careful medication reconciliation during care transitions.
3. A 41-year-old female (74 kg) with migraines reports that her new medication is not working. Medical history includes migraine and depression. Allergies: none. Current medications: sumatriptan 50 mg PO at onset of migraine (may repeat once in 2 hours; max 200 mg/day), propranolol 40 mg PO twice daily, sertraline 50 mg PO daily. She has been taking sumatriptan every morning to prevent headaches. What is the best strategy for managing this medication timing issue?
   Answer: Use sumatriptan only at migraine onset and continue propranolol as scheduled for prevention This question evaluates appropriate use and scheduling of abortive versus prophylactic migraine therapies. The key patient-specific factor is misuse of sumatriptan as daily prophylaxis instead of acute treatment, leading to inefficacy and potential overuse. Choice A is the best strategy as sumatriptan is for acute migraines, while propranolol continues as prevention, optimizing both efficacy and safety. Choice B is incorrect because daily sumatriptan is not for prophylaxis and risks medication-overuse headache; choice C is suboptimal as they have distinct roles; choice D is wrong since sertraline does not affect absorption. Differentiating acute from preventive timing prevents rebound headaches. A decision framework is to educate on indications to ensure proper use and adherence.
4. A 69-year-old female (weight 58 kg) is seen for follow-up after a deep vein thrombosis (DVT) and is confused about how to take her medications. Medical history: DVT (2 months ago), atrial fibrillation, hypertension, osteoarthritis. Allergies: none. Current medications: warfarin 5 mg by mouth daily (goal INR 2–3), amiodarone 200 mg by mouth daily, metoprolol succinate 50 mg by mouth daily, and acetaminophen 650 mg by mouth every 6 hours as needed. Pertinent labs: INR 3.6 (goal 2.0–3.0), SCr 0.9 mg/dL (0.6–1.3), AST 30 U/L (10–40), ALT 34 U/L (7–56). The patient reports starting "a new green smoothie" daily and taking warfarin at varying times. Which medication requires patient counseling on scheduling?
   Answer: Warfarin: take at the same time each day and keep vitamin K intake consistent This question tests proper warfarin administration and the importance of consistent scheduling. The patient's INR is supratherapeutic (3.6 vs goal 2-3) and she reports both starting a green smoothie (high vitamin K) and taking warfarin at varying times, both of which affect anticoagulation control. Warfarin requires consistent daily timing and stable vitamin K intake because fluctuations in either can cause INR variability and increase bleeding or clotting risk. Option A is incorrect as metoprolol succinate can be taken any time and doesn't cause insomnia, option C wrongly suggests alternating amiodarone dosing which would cause erratic drug levels, and option D incorrectly states acetaminophen must be taken on empty stomach for INR reasons. The clinical pearl is that warfarin's narrow therapeutic index requires consistent administration time (same time daily ± 2 hours) and stable dietary vitamin K intake - sudden changes in either can destabilize anticoagulation and require more frequent INR monitoring.
5. A 34-year-old male (80 kg) is prescribed a new medication for acne. Medical history includes acne vulgaris and attention-deficit/hyperactivity disorder. Allergies: none. Current medications: isotretinoin 20 mg PO twice daily (new), methylphenidate ER 36 mg PO every morning, vitamin A supplement 10,000 units PO daily (self-started). Labs: AST 55 U/L (10–40), ALT 62 U/L (7–56), triglycerides 280 mg/dL (normal <150). Which medication should be discontinued based on current indications and safety?
   Answer: Vitamin A supplement 10,000 units PO daily This question tests safety considerations for vitamin A supplementation in patients on isotretinoin therapy. The key patient-specific factor is elevated liver enzymes and triglycerides, exacerbated by excessive vitamin A intake leading to hypervitaminosis A. Choice B is the medication to discontinue as vitamin A supplements increase toxicity risk when added to isotretinoin, a vitamin A derivative. Choice A is incorrect because methylphenidate is for ADHD without interaction; choice C is suboptimal as isotretinoin is indicated for acne; choice D is wrong since acetaminophen does not protect the liver and may worsen hepatotoxicity. Limiting total vitamin A exposure prevents adverse effects like hepatotoxicity. A decision framework involves screening for supplements in retinoid users to ensure safe cumulative dosing.
6. A 50-year-old female (64 kg) with bipolar disorder presents for counseling on a new antibiotic. Medical history includes bipolar disorder and acne rosacea. Allergies: none. Current medications: lithium carbonate 300 mg PO three times daily, topical metronidazole gel daily. New prescription: naproxen 500 mg PO twice daily for knee pain. Labs: SCr 1.0 mg/dL, lithium level 0.9 mEq/L (0.6–1.2). Which potential drug interaction is most concerning?
   Answer: Naproxen can increase lithium concentrations and toxicity risk This question evaluates pharmacokinetic interactions between NSAIDs and mood stabilizers. The key patient-specific factor is stable lithium levels that could be disrupted by naproxen, leading to toxicity. Choice A is most concerning as naproxen reduces lithium clearance, increasing concentrations and risk of adverse effects like tremor or confusion. Choice B is incorrect because lithium does not affect naproxen absorption; choice C is suboptimal as topical metronidazole has minimal systemic interaction; choice D is wrong since no chelation requires separation. Monitoring lithium levels during NSAID use ensures safety. A decision framework is to consider NSAID alternatives like acetaminophen in lithium patients to avoid renal effects.
7. A 59-year-old female (72 kg) presents with new onset ankle swelling and constipation. Medical history includes hypertension and chronic stable angina. Allergies: none. Current medications: amlodipine 10 mg PO daily, metoprolol tartrate 50 mg PO twice daily, isosorbide mononitrate ER 60 mg PO every morning, nitroglycerin 0.4 mg sublingual as needed. Vitals: BP 118/72 mmHg, HR 58 bpm. Which medication should be discontinued based on current indications and safety due to therapeutic overlap?
   Answer: Amlodipine 10 mg PO daily This question examines identification of adverse effects and therapeutic duplication in angina and hypertension management. The key patient-specific factor is new ankle swelling and constipation, common side effects of amlodipine, with no indication for its continued use alongside other agents. Choice C is the medication to discontinue as amlodipine causes edema and constipation, and blood pressure is controlled without it. Choice A is incorrect because nitroglycerin is for acute relief; choice B is suboptimal as isosorbide is for chronic angina prevention; choice D is wrong since metoprolol is for rate control without duplication. Avoiding unnecessary calcium channel blockers prevents side effects in stable patients. A clinical pearl is to review regimens for overlapping therapies and deprescribe based on current symptoms and control.
8. A 57-year-old male (83 kg) is starting a new medication for neuropathic pain. Medical history includes diabetic neuropathy, type 2 diabetes, and chronic kidney disease stage 4. Allergies: none. Current medications: insulin glargine 24 units nightly, insulin lispro with meals, gabapentin 300 mg PO three times daily (newly increased), duloxetine 60 mg PO daily. Labs: SCr 2.8 mg/dL, estimated creatinine clearance 22 mL/min. Which potential drug therapy issue is most concerning?
   Answer: Gabapentin dose is too high for renal function and may cause CNS adverse effects This question assesses dose adjustment needs for renally cleared medications in CKD patients. The key patient-specific factor is stage 4 CKD with reduced creatinine clearance, where gabapentin accumulation can cause CNS toxicity. Choice A is most concerning as gabapentin requires dose reduction in low CrCl to prevent sedation or dizziness. Choice B is incorrect because duloxetine timing does not interact with insulin; choice C is suboptimal as no separation is needed; choice D is wrong since gabapentin is indicated for neuropathy. Renal dosing guidelines ensure safety by preventing toxicity. A clinical pearl is to calculate CrCl for all renally eliminated drugs and adjust accordingly.
9. A 54-year-old male (85 kg) comes in for counseling after starting a new medication for Helicobacter pylori. Medical history includes peptic ulcer disease and hyperlipidemia. Allergies: none. Current medications: clarithromycin 500 mg PO twice daily (new), amoxicillin 1000 mg PO twice daily (new), omeprazole 20 mg PO twice daily (new), atorvastatin 40 mg PO nightly. Labs: AST 30 U/L, ALT 34 U/L, SCr 1.0 mg/dL. Which potential drug interaction is most concerning?
   Answer: Clarithromycin can increase atorvastatin concentrations and myopathy risk This question examines CYP3A4 inhibition interactions increasing statin toxicity risk. The key patient-specific factor is clarithromycin, a strong inhibitor, combined with atorvastatin, raising myopathy potential. Choice A is most concerning as clarithromycin inhibits atorvastatin metabolism, increasing concentrations and rhabdomyolysis risk. Choice B is incorrect because omeprazole does not chelate amoxicillin; choice C is suboptimal as atorvastatin does not induce clarithromycin; choice D is wrong since amoxicillin is twice daily for H. pylori. Holding or adjusting statins during macrolide therapy ensures safety. A decision framework is to check for CYP interactions in lipid-lowering regimens with new antibiotics.
10. A 56-year-old female (84 kg) reports persistent constipation and requests advice. Medical history includes chronic pain and hypothyroidism. Allergies: none. Current medications: oxycodone ER 20 mg PO twice daily, oxycodone IR 5 mg PO every 6 hours as needed, levothyroxine 88 mcg PO daily. Labs: TSH 2.0 mIU/L (0.4–4.0), SCr 0.9 mg/dL. A new prescription is written for docusate 100 mg PO twice daily. Which medication is indicated for prevention and treatment of opioid-induced constipation?
    Answer: Senna 8.6 mg: 2 tablets PO at bedtime This question evaluates indications for stimulant laxatives in opioid-induced constipation management. The key patient-specific factor is chronic opioid use causing constipation, where prophylactic stimulant therapy is preferred over stool softeners alone. Choice B is indicated as senna effectively prevents and treats opioid-induced constipation by stimulating bowel motility. Choice A is incorrect because docusate is often ineffective monotherapy for OIC; choice C is suboptimal as loperamide is an antidiarrheal, not for constipation; choice D is wrong since ondansetron is for nausea, not bowel issues. Stimulant laxatives are first-line for OIC due to their mechanism countering opioid effects on gut motility. A clinical pearl is to initiate laxatives concurrently with opioids to maintain bowel regularity and patient comfort.
11. A 68-year-old male (92 kg) with chronic obstructive pulmonary disease (COPD) comes to the pharmacy for a new inhaler. Medical history includes COPD and benign prostatic hyperplasia. Allergies: none. Current medications: tiotropium inhaler 2 inhalations daily, albuterol HFA 2 puffs every 4–6 hours as needed, tamsulosin 0.4 mg PO nightly. New prescription: ipratropium inhaler 2 puffs four times daily. He reports dry mouth and difficulty urinating. Which medication should be discontinued based on current indications and safety due to therapy duplication?
    Answer: Ipratropium inhaler four times daily This question examines anticholinergic burden and therapeutic duplication in COPD management. The key patient-specific factor is dry mouth and urinary issues from adding ipratropium to tiotropium, both anticholinergics. Choice C is the medication to discontinue as ipratropium duplicates tiotropium's action, increasing anticholinergic side effects without added benefit. Choice A is incorrect because albuterol is a complementary bronchodilator; choice B is suboptimal as tiotropium is the long-acting agent; choice D is wrong since tamsulosin is for BPH. Avoiding duplicate anticholinergics reduces adverse effects like urinary retention. A decision framework involves selecting long-acting over short-acting agents for maintenance therapy in COPD.
12. A 49-year-old male (77 kg) is initiating therapy for gout flare prophylaxis while starting urate-lowering therapy. Medical history includes gout and hypertension. Allergies: none. Current medications: allopurinol 100 mg PO daily (new), colchicine 0.6 mg PO daily (new), lisinopril 20 mg PO daily. Labs: SCr 1.2 mg/dL, AST 24 U/L, ALT 22 U/L. He asks when to start colchicine relative to allopurinol. What is the most appropriate dosing schedule for this patient?
    Answer: Take colchicine daily starting with allopurinol initiation to reduce flare risk This question assesses the appropriate scheduling of prophylactic therapy during initiation of urate-lowering treatment for gout, emphasizing indications for flare prevention. The key patient-specific factor is the 49-year-old male's new initiation of allopurinol, which increases the risk of acute gout flares during the early treatment phase due to rapid uric acid mobilization. Taking colchicine daily starting with allopurinol initiation is the best choice as it provides effective prophylaxis against flares, aligning with guidelines recommending 3-6 months of coverage or until uric acid normalization. Starting colchicine only after 6 months of allopurinol misses the critical high-risk period for flares, while using colchicine as needed and stopping allopurinol during flares disrupts urate-lowering continuity and is not recommended. Taking both medications only on weekends lacks evidence and could lead to inconsistent efficacy and increased toxicity risks from irregular dosing. A transferable clinical pearl is that proper timing of gout prophylaxis enhances efficacy by mitigating early flares, which improves adherence, while ensuring safety through consistent low-dose regimens to avoid gastrointestinal or other adverse effects. Decision frameworks for scheduling should consider disease-specific guidelines, such as those from the American College of Rheumatology, to balance preventive benefits with long-term treatment goals.
13. A 26-year-old female (weight 54 kg) is prescribed a combined oral contraceptive and asks how to start it. Medical history: none. Allergies: none. Current medications: ethinyl estradiol/levonorgestrel 30 mcg/150 mcg 1 tablet by mouth daily (new), sertraline 50 mg by mouth daily. Pertinent labs: blood pressure 118/72 mmHg, SCr 0.8 mg/dL (0.6–1.3), AST 20 U/L (10–40), ALT 18 U/L (7–56). She is not currently pregnant and had unprotected intercourse 3 days ago; her next menstrual period is expected in 10 days. Which medication requires patient counseling on scheduling?
    Answer: Ethinyl estradiol/levonorgestrel: take 1 tablet at the same time daily; if starting today (quick start), use backup contraception for 7 days This question tests proper initiation and scheduling of combined oral contraceptives for optimal efficacy. The key counseling point is that combined oral contraceptives must be taken at the same time daily to maintain stable hormone levels and contraceptive efficacy, with backup contraception needed for 7 days if using the "quick start" method (starting immediately rather than waiting for menses). Option B correctly identifies this need for consistent daily timing and backup protection. Option A incorrectly suggests weekend dose-skipping for sertraline which would destabilize antidepressant therapy, option C wrongly recommends doubling the contraceptive dose, and option D dangerously suggests intermittent use which provides no contraceptive protection. The clinical pearl is that consistent daily administration of oral contraceptives at the same time (within a 3-hour window) optimizes efficacy - missed doses or erratic timing increases breakthrough bleeding and pregnancy risk, requiring specific missed-dose protocols based on timing.
14. A 62-year-old female (66 kg) with osteoporosis is starting a new medication. Medical history includes osteoporosis and GERD. Allergies: none. Current medications: calcium citrate 315 mg PO twice daily, vitamin D3 2000 units PO daily, famotidine 20 mg PO twice daily. New prescription: alendronate 70 mg PO once weekly. What is the most appropriate dosing schedule for this patient?
    Answer: Take alendronate 70 mg first thing in the morning with plain water, wait at least 30 minutes before food/other meds, and remain upright This question tests proper administration scheduling for bisphosphonates to minimize esophageal irritation in osteoporosis treatment. The key patient-specific factor is GERD history, necessitating strict adherence to dosing instructions to prevent GI complications. Choice C is most appropriate as alendronate should be taken fasting with plain water, followed by a 30-minute wait and upright posture to ensure safe esophageal transit. Choice A is incorrect due to post-breakfast timing and inadequate upright duration; choice B is suboptimal as bedtime dosing increases reflux risk; choice D is wrong since calcium impairs absorption. Timing bisphosphonates correctly enhances efficacy by improving absorption and safety by reducing esophagitis risk. A decision framework involves educating on fasting and posture requirements for all oral bisphosphonates.
15. A 65-year-old female (69 kg) is prescribed a new medication for overactive bladder. Medical history includes overactive bladder, narrow-angle glaucoma, and hypertension. Allergies: none. Current medications: latanoprost ophthalmic 1 drop each eye nightly, hydrochlorothiazide 25 mg PO daily. New prescription: oxybutynin ER 10 mg PO daily. Labs: SCr 0.8 mg/dL. Which potential drug therapy issue is most concerning?
    Answer: Oxybutynin is contraindicated in narrow-angle glaucoma This question tests contraindications of anticholinergic agents in glaucoma patients. The key patient-specific factor is narrow-angle glaucoma, where oxybutynin can precipitate angle closure by pupil dilation. Choice A is most concerning as oxybutynin is contraindicated in uncontrolled narrow-angle glaucoma due to risk of acute attacks. Choice B is incorrect because hydrochlorothiazide does not affect oxybutynin absorption; choice C is suboptimal as latanoprost and oxybutynin have no hypotensive interaction; choice D is wrong since ER formulation is once daily. Avoiding systemic anticholinergics preserves vision safety. A clinical pearl is to screen for glaucoma before prescribing bladder antimuscarinics and consider alternatives.
16. A 66-year-old male (78 kg) is newly prescribed doxycycline for pneumonia and asks about his supplements. Medical history includes hypertension and iron-deficiency anemia. Allergies: none. Current medications: doxycycline 100 mg PO twice daily (new), ferrous sulfate 325 mg PO daily, multivitamin with minerals daily, losartan 50 mg PO daily. Labs: SCr 1.0 mg/dL, AST 26 U/L, ALT 24 U/L. What is the best strategy for managing this medication timing issue to avoid reduced antibiotic absorption?
    Answer: Separate doxycycline from iron/multivitamins by at least 2–4 hours This question evaluates management of chelation interactions between tetracyclines and cations to preserve antibiotic efficacy. The key patient-specific factor is concurrent iron and multivitamin use, which can bind doxycycline and reduce its absorption. Choice B is the best strategy as separating doxycycline from iron/multivitamins by 2–4 hours prevents chelation and maintains therapeutic levels. Choice A is incorrect because co-administration worsens nausea and interaction; choice C is suboptimal as bedtime-only dosing does not address full regimen; choice D is wrong since losartan has no interaction requiring discontinuation. Proper timing ensures antibiotic efficacy and safety by avoiding subtherapeutic levels leading to resistance. A decision framework is to counsel separation for all tetracyclines with divalent/trivalent cations.
17. A 33-year-old female (weight 62 kg) requests counseling after being prescribed doxycycline for acne and starting a prenatal vitamin because she is trying to conceive. Medical history: acne vulgaris, no chronic conditions. Allergies: none. Current medications: doxycycline 100 mg by mouth twice daily (new), prenatal vitamin with iron 1 tablet by mouth daily (new), and magnesium oxide 400 mg by mouth daily for constipation. Pertinent labs: SCr 0.7 mg/dL (0.6–1.3), AST 18 U/L (10–40), ALT 16 U/L (7–56). She reports taking all medications together with breakfast. What is the best strategy for managing this medication timing issue?
    Answer: Separate doxycycline from iron- and magnesium-containing products by at least 2 hours before or 4–6 hours after; take doxycycline with a full glass of water and avoid lying down immediately This question tests management of tetracycline-polyvalent cation interactions affecting drug absorption. The key issue is that doxycycline forms insoluble chelate complexes with iron (in prenatal vitamin) and magnesium, reducing its bioavailability by up to 80% when taken together. The optimal strategy is temporal separation: take doxycycline at least 2 hours before or 4-6 hours after iron/magnesium-containing products, with a full glass of water, avoiding immediate recumbency to prevent esophageal irritation. Option A incorrectly suggests taking them together, option C's bedtime administration with prenatal vitamin maintains the interaction, and option D unnecessarily stops the prenatal vitamin when separation is sufficient. The clinical pearl is that tetracycline antibiotics require careful scheduling around dairy products, antacids, and supplements containing calcium, iron, magnesium, or aluminum - proper separation preserves antibiotic efficacy while allowing continued use of necessary supplements.
18. A 72-year-old male (weight 80 kg) is discharged after a transient ischemic attack (TIA) and brings his updated medication list to the pharmacy. Medical history: TIA, hypertension, type 2 diabetes, hyperlipidemia, peptic ulcer disease (remote). Allergies: aspirin (urticaria). Current medications: clopidogrel 75 mg by mouth daily (new), atorvastatin 80 mg by mouth nightly (new), metformin 1,000 mg by mouth twice daily, amlodipine 10 mg by mouth daily, and omeprazole 20 mg by mouth daily. Pertinent labs: A1c 7.4% (goal <7% individualized), SCr 1.0 mg/dL (0.6–1.3), AST 28 U/L (10–40), ALT 30 U/L (7–56). Which potential drug interaction is most concerning?
    Answer: Clopidogrel 75 mg daily with omeprazole 20 mg daily (reduced antiplatelet activation) This question tests recognition of clinically significant drug-drug interactions in a post-TIA patient. The key interaction is between clopidogrel and omeprazole, where omeprazole (a CYP2C19 inhibitor) reduces the conversion of clopidogrel to its active metabolite, potentially decreasing antiplatelet efficacy by 25-50%. This interaction is most concerning because reduced antiplatelet activity increases the risk of recurrent cerebrovascular events in this high-risk post-TIA patient. Option B is incorrect as there's no interaction between atorvastatin and metformin causing hypoglycemia, option C is false as omeprazole doesn't affect amlodipine's blood pressure control, and option D is wrong as clopidogrel doesn't affect statin efficacy. The clinical pearl is that PPIs vary in their CYP2C19 inhibition potential - pantoprazole or lansoprazole are preferred over omeprazole/esomeprazole when concurrent clopidogrel is necessary. The FDA specifically warns against this combination due to reduced cardiovascular protection.
19. A 45-year-old male (95 kg, 180 cm) visits urgent care for acute low back pain after lifting a heavy object 2 days ago. Medical history includes peptic ulcer disease with prior gastrointestinal bleed (2 years ago) and hypertension. Allergies: none. Current medications: lisinopril 10 mg PO daily, pantoprazole 40 mg PO daily. Labs: SCr 0.9 mg/dL, hemoglobin 14.0 g/dL. The prescriber adds ibuprofen 800 mg PO three times daily as needed for pain. Which potential drug therapy issue is most concerning?
    Answer: Ibuprofen is contraindicated due to prior gastrointestinal bleed history This question assesses contraindications and safety concerns with NSAID use in patients with a history of gastrointestinal bleeding. The key patient-specific factor is the prior GI bleed, which increases the risk of recurrence with ibuprofen despite pantoprazole prophylaxis. Choice A is the most concerning issue because ibuprofen is contraindicated in patients with a history of GI bleed due to heightened ulcer risk, even with PPI protection. Choice B is incorrect as pantoprazole does not significantly affect ibuprofen absorption; choice C is wrong because lisinopril does not enhance ibuprofen's analgesic effects or overdose risk; choice D is suboptimal as bedtime scheduling does not address the primary safety concern. This underscores the need to evaluate NSAID use in high-risk GI patients. A decision framework involves prioritizing non-NSAID alternatives like acetaminophen for pain in such cases to ensure safety.
20. A 38-year-old female (68 kg) is starting treatment for a urinary tract infection. Medical history includes recurrent cystitis and depression. Allergies: none. Current medications: sertraline 100 mg PO daily, combined oral contraceptive 1 tablet PO daily. New prescription: nitrofurantoin monohydrate/macrocrystals 100 mg PO twice daily for 5 days. She asks how to take it to reduce stomach upset and improve effectiveness. What is the most appropriate dosing schedule for this patient?
    Answer: Take nitrofurantoin 100 mg twice daily with food This question assesses optimal scheduling of nitrofurantoin to minimize GI upset and enhance tolerability in UTI treatment. The key patient-specific factor is the need to reduce stomach upset while ensuring effective absorption for cystitis management. Choice B is most appropriate as taking nitrofurantoin with food decreases GI irritation without significantly impacting bioavailability. Choice A is incorrect because once-daily dosing is for prophylaxis, not acute treatment, and empty stomach increases nausea; choice C is suboptimal as magnesium antacids may chelate and reduce absorption; choice D is wrong since as-needed use is ineffective for infection eradication. Proper timing with meals improves adherence by enhancing safety and comfort. A clinical pearl is to counsel on food co-administration for antibiotics prone to GI side effects to optimize therapy completion.

Start this quiz